News
-
Adherium has announced that Monaghan Medical is set to begin a pilot program to launch Adherium’s Hailie inhaler monitoring platform in eight US respiratory centers by the end of the first quarter of 2021, with… Read more . . .
-
Dutch DPI developer PureIMS has announced the appointment of Bram van Dijck as its new Chief Executive Officer, succeeding Reinier Schwietert, who is stepping down as CEO but will remain with the company. Van Dijck was… Read more . . .
-
Marinomed Biotech has announced plans for a Phase 4 trial of Carragelose iota-carrageenan nasal spray in healthcare professionals in contact with COVID-19 patients to study the ability of the nasal spray to reduce symptoms of… Read more . . .
-
The batch of new product specific guidances published by the FDA in November 2020 include guidances for generic OINDPs referencing Valtoco diazepam nasal spray, Primatene Mist epinephrine MDI, and Spiriva Respimat tiotropium bromide SMI. The… Read more . . .
-
According to inhalation CDMO Vectura, the United States Court of Appeals for the Federal Circuit has upheld a ruling by the District Court of Delaware against GlaxoSmithKline for infringing on a Vectura patent and has… Read more . . .
-
Zeteo Biomedical said that the company will supply its ZEOx2 nasal delivery system and unit dose packaging for use with a shelf-stable SARS-CoV-2 vaccine in development at the Nanovaccine Institute at Iowa State University. Zeteo is… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the RAPID Phase 3 trial of etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). A previous Phase 3 trial, NODE-301, failed to meet its primary… Read more . . .
-
The Drug Delivery to the Lungs (DDL) meeting was due to return to the Edinburgh International Conference Centre December 9-11 this year following the celebration of its 30th anniversary and it’s 15th year bringing hundreds… Read more . . .
-
Revelation Biosciences, which announced in October 2020 that the TGA had approved plans for a Phase 1 study of its REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), said that it has now initiated the trial. According… Read more . . .
-
CDMO Kindeva Drug Delivery announced that it has broken ground on a new 137,500 sq ft headquarters building in Woodbury, MN, USA; the company anticipates that the building will be opened in the latter half… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.